On Jun. 29, 2021, Paratek Pharmaceuticals announced it had delivered the first procurement of NUZYRA to the Biomedical Advanced Research and Development Authority (BARDA) for the treatment of pulmonary anthrax. This procurement was valued at ~$38 million.